Categories
Health

No proof a booster shot is required, says Dr. Ashish Jha

Covid booster doses are currently not required, said the dean of the School of Public Health at Brown University on Friday, as highly transmissible new variants test the protection of available vaccines.

“Let me tell you where we are: the data is very clear, if you got your two shots from Moderna or Pfizer or a single shot from J&J you have a very high level of protection against all variants, including Delta” said Dr. Ashish Jha. “I haven’t seen any evidence yet that anyone needs a third shot.”

Jha’s comments come after Pfizer and BioNTech announced Thursday that they are developing a Covid-19 booster shot that will target the Delta variant. Company officials say another vaccination may be needed as immunity to the vaccine appears to decline over time.

In CNBC’s The News with Shepard Smith, Jha emphasized the importance of waiting for the dates when it comes to a booster shot.

“When this evidence comes along, and of course we will want to take that into account, I think I think it is unlikely that we will need third shots for most people,” Jha said.

The Centers for Disease Control and Prevention and the Food and Drug Administration issued a joint statement stating that Americans who are fully vaccinated do not need a booster vaccination.

“Americans who have been fully vaccinated currently do not need a booster vaccination. FDA, CDC, and [the National Institutes of Health] are involved in a science-based, rigorous process to check if or when a refresher might be needed, “said a joint statement released Thursday evening.

Categories
Health

Dementia skilled says proof ‘wasn’t enough’ for approval

Dementia expert Dr. Jason Karlawish told CNBC he’s skeptical of the Food and Drug Administration’s approval of Biogen’s Alzheimer’s disease drug, Aduhelm, saying “the evidence to approve the drug wasn’t sufficient.”

“Another study is needed to establish whether this drug, in fact, is effective. Unfortunately, the FDA approved the drug for marketing, although they also do want another study,” the co-director of the Penn Memory Center at the University of Pennsylvania said on Monday following the agency’s formal OK.

The FDA’s approval marks the first new treatment for Alzheimer’s in nearly two decades. Alzheimer’s is a progressive neurodegenerative disorder that slowly destroys memory and thinking skills. More than 6 million Americans live with the disease, according to estimates by the Alzheimer’s Association. 

Karlawish told “The News with Shepard Smith” that there are a lot of promising Alzheimer’s drugs in the pipeline.  

“I’m optimistic about the coming future here, so I have hope. I just think this is not the drug upon which to pin our hopes,” he said. “Desperation should drive funding for Alzheimer’s research, it should not drive the interpretation of scientific evidence.”

Clinical trials found some patients who got the approved dose of Aduhelm experienced painful brain swelling.

“What you’re asking someone to do, is to take a chance at uncertain benefit, but known risk,” Karlawish said of prescribing the drug to patients.

The FDA said it will continue to monitor the drug as it reaches the U.S. market. The agency granted approval on the condition that Biogen conduct another clinical trial. 

Karlawish told host Shepard Smith that Biogen will face a challenge in “how to do that study when the drug is also available for clinical prescribing.” 

Representatives for Biogen and for the FDA did not immediately return requests for comment on Karlawish’s statements.

Categories
Health

Scientists Don’t Need to Ignore the Wuhan ‘Lab Leak’ Concept, Regardless of No New Proof

As scientists find more animal coronaviruses, they can recognize more and more pieces of SARS-CoV-2 spread out among them. Researchers have also been able to reconstruct some of the evolutionary steps by which SARS-CoV-2 evolved into a potential human pathogen while it was still infecting animals.

This pattern is probably one that’s been followed by many viruses that are now major burdens on human health. H.I.V., for example, most likely had its origin in the early 1900s, when hunters in West Africa got infected with viruses that infected chimpanzees and other primates.

But some scientists thought it was too soon to conclude something similar happened in the case of SARS-CoV-2. After all, the coronavirus first came to light in the city of Wuhan, home to the Wuhan Institute of Virology, where researchers study dozens of strains of coronaviruses collected in caves in southern China.

Still, that a top lab studying this family of viruses happens to be located in the same city where the epidemic emerged could very well be a coincidence. Wuhan is an urban center larger than New York City, with a steady flow of visitors from other parts of China. It also has many large markets dealing in wildlife brought from across China and beyond. When wild animals are kept in close quarters, viruses have an opportunity to jump from species to species, sometimes resulting in dangerous recombinations that can lead to new diseases.

That lab’s research began after another coronavirus led to the SARS epidemic in 2002. Researchers soon found relatives of that virus, called SARS-CoV, in bats, as well as civet cats, which are sold in Chinese markets. The discovery opened the eyes of scientists to all the animal coronaviruses with the potential of spilling over the species line and starting a new pandemic.

Virologists can take many measures to reduce the risk of getting infected with the viruses they study. But over the years, some accidents have happened. Researchers have gotten sick, and they’ve infected others with their experimental viruses.

In 2004, for example, a researcher at the National Institute of Virology in Beijing got infected with the coronavirus that causes SARS. She passed it on to others, including her mother, who died from the infection.

Categories
Health

Jury can hear restricted proof of CEO way of life

Theranos founder Elizabeth Holmes leaves the Robert F. Peckham Federal Building with her defense team in downtown San Jose, Calif., on Tuesday, May 4, 2021.

MediaNews Group/The Mercury News via Getty Images | MediaNews Group | Getty Images

Jurors in the trial of Elizabeth Holmes will hear evidence about her extravagant lifestyle as Theranos CEO but with some limitations.

That’s the ruling issued by U.S. District Court Judge Edward Davila late Saturday as part of a 100 page response to motions in Holmes’ upcoming criminal trial.

The judge granted in part Holmes’ motion to exclude evidence referencing her extravagant lifestyle outside of her position as chief executive of the blood-testing start-up.

“The Government may introduce evidence that Holmes enjoyed a lifestyle as Theranos CEO that is comparable to those of other tech company CEOs. This includes salary, travel, celebrity, and other perks and benefits commensurate with the position,” Davila wrote in the filing.

However, “references to specific purchases or details reflecting branding of clothing, hotels, or other personal items is not relevant, and the prejudicial effect of that evidence outweighs any probative value,” the judge added.

The ruling is a partial victory for Holmes as prosecutors cannot introduce details about Holmes’ specific purchases and personal items outside of her position as CEO. Holmes lived in an expensive rental home, traveled by private jet, stayed at luxury hotels and employed Theranos-paid assistants to run her lavish shopping sprees.

“Each time Holmes made an extravagant purchase, it is reasonable to infer that she knew her fraudulent activity allowed her to pay for those items,” Davila wrote. “While the benefits of these purchases are not as directly tied to the fraud…it may still be probative of Holmes’ scienter.”

The ruling comes two weeks after Holmes battled it out with prosecutors in court over whether details of her wealth, lifestyle and perks she attained as CEO would be relevant to jurors in her trial.

At the height of Theranos, the start-up was valued at $9 billion and Holmes was touted as the world’s youngest self-made woman billionaire. The company collapsed in 2018 following a Wall Street Journal investigation that revealed failings in the blood-testing technology.

Davila ruled on more than 20 dueling motions on what jurors can hear in her trial, scheduled to begin on Aug. 30.

A motion by the government to admit business-related text messages between Holmes and her co-defendant Ramesh “Sunny” Balwani was denied by Davila.

Prosecutors say the messages show the two top executives knew how much trouble Theranos was in before it collapsed. In a November 2014 text to Holmes, Balwani describes one Theranos lab as a “f*cking disaster zone,” adding he would “work on fixing this.”

Holmes and Balwani have both pled not guilty to a dozen criminal wire fraud charges in connection with deceiving investors, patients and doctors.

Categories
Business

Jobless Claims Fall, Providing Recent Proof of a Restoration: Dwell Updates

Here’s what you need to know:

Credit…Karsten Moran for The New York Times

New claims for unemployment benefits fell last week to the lowest level of the pandemic, the government reported on Thursday, offering fresh evidence of the labor market’s recovery.

A total of 566,000 workers filed first-time claims for state benefits during the week that ended April 17, the Labor Department said, a decrease of 57,000 from the previous week’s revised figure. In addition, 133,000 new claims were filed for Pandemic Unemployment Assistance, a federal program that covers freelancers, part-timers and others who do not qualify for state benefits.

Neither figure is seasonally adjusted.

“The bigger story — even though we’re going to see volatility week to week — is that the labor market continues to heal and labor demand is coming back quite strongly in line with robust growth,” said Kathy Bostjancic, chief U.S. financial economist at Oxford Economics.

Warmer weather, more extensive coronavirus vaccination efforts and a stream of government assistance that has enabled consumer spending have all contributed to recent gains.

Encumbrances remain. The labor market is weighed down by continuing anxiety about coronavirus infections and the demands of child care when regular school schedules have been disrupted.

According to the Census Bureau’s weekly Household Pulse Survey, more than four million people who were unemployed in March said they were not working because they were afraid of catching Covid-19.

“It’s important to keep in mind that the trend is going in the right direction,” said Heidi Shierholz, director of policy at the left-leaning Economic Policy Institute, “but we’re still at crisis levels of unemployment claims.”

The weekly level of new claims is still near historical highs recorded before the pandemic. And there are roughly 8.4 million fewer jobs than there were in early 2020.

The long-term unemployed face particular hurdles. A new report from the California Policy Lab, a research institute based at the University of California, said some states were prematurely ending extended unemployment insurance because of the way they count claims.

Southwest Airlines earned $116 million in the first quarter after its first annual loss in half a century last year.Credit…Lucy Nicholson/Reuters

The worst appears to be over for airlines. Now, it’s just a matter of waiting for the summer travel frenzy to begin.

American Airlines and Southwest Airlines on Thursday were the last two major U.S. airlines to report financial results for the first three months of the year. American lost nearly $1.3 billion, while Southwest earned $116 million, a welcome profit after weathering its first annual loss in half a century last year.

“While the pandemic is not over, we believe the worst is behind us, in terms of the severity of the negative impact on travel demand,” Gary Kelly, Southwest’s chairman, said in a statement. “Vaccinations are on the rise, and Covid-19 hospitalizations in the United States are down significantly from their peak in January 2021. As a result, we are experiencing steady weekly improvements in domestic leisure bookings, which began in mid-February 2021.”

That sentiment is shared across the industry.

“With the momentum underway from the first quarter, we see signs of continued recovery in demand,” Doug Parker, American’s chief executive, said in a statement on Thursday. His counterpart at United Airlines issued a similarly hopeful statement this week, despite posting a loss of $1.4 billion. Last week, Delta Air Lines reported a $1.2 billion loss.

The industry has been buoyed by federal support, receiving $54 billion in grants to pay workers over the past year and another $25 billion in loans. Mr. Kelly of Southwest credited that support for the airline’s slight profit, saying that the airline would have lost $1 billion in the first quarter without it.

Southwest was also buoyed by its limited exposure to corporate and international travel, which have been slow to rebound and are lucrative parts of the business for American, Delta and United. Leisure travel within the United States, which all of the airlines serve, is almost fully recovered.

Air travel started to recover meaningfully in early March, with Transportation Security Administration data showing a steady rise in the number of people screened at airport security checkpoints relative to the same period in 2019. That surge has subsided somewhat since earlier this month, with screenings down about 42 percent over the past week compared with 2019.

Southwest said demand for travel continues to improve with summer fast approaching and customers once again feeling comfortable making travel plans further out. The airline estimates that it has about 35 percent of expected bookings in place for June and 20 percent for July.

Thomas Gottstein, the chief executive of Credit Suisse, described the loss as “unacceptable.” If not for the collapse of Archegos, the bank said it would have made a pretax profit of 3.6 billion francs.Credit…Ennio Leanza/Keystone, via Associated Press

Credit Suisse said on Thursday that it suffered a loss in the first quarter stemming from loans it made to the collapsed investment fund Archegos Capital Management, a debacle that has prompted Switzerland’s financial regulator to investigate whether the bank was doing a poor job monitoring the riskiness of its investments.

The loss of 252 million Swiss francs, about $275 million, from January through March, came after a loss of 4.4 billion francs from Archegos that wiped out a big increase in revenue. Credit Suisse also said on Thursday that it had sold bonds to investors to raise $2 billion to shore up its capital.

The bank expects additional losses from Archegos of about $655 million as it finishes winding down its exposure to the firm, Thomas Gottstein, the chief executive of Credit Suisse, said during a conference call with reporters Thursday.

The bank, based in Zurich, has suffered a series of calamities this year that have severely damaged its reputation and finances. Swiss regulators are also investigating a spying scandal and Credit Suisse’s sale of $10 billion in funds packaged by Greensill Capital. The funds were based on financing provided to companies, many of which had low credit ratings or were not rated at all. Greensill collapsed in March, and its ties to former Prime Minister David Cameron of Britain have caused a political scandal.

Mr. Gottstein promised Thursday that Credit Suisse would overhaul its systems for tracking risk to avoid future disasters. Several top executives have already left the bank as part of a management shake-up, including Lara Warner, the chief risk and compliance officer.

Credit Suisse also plans to pare back the size of a unit that serves hedge fund clients and was involved in the Archegos losses. Mr. Gottstein declined to say whether the debacle would lead to major changes at Credit Suisse’s investment bank, which has a large presence in New York.

But he suggested that Credit Suisse would not retreat from investment banking. “The underlying results show that the strategy is working,” he told reporters. “I wouldn’t say that because we had two disappointing incidents we should throw the whole strategy overboard.”

If not for the Archegos loss, Credit Suisse would have made a pretax profit of 3.6 billion francs, the bank said. Revenue for the quarter rose 30 percent to 7.6 billion francs as Credit Suisse raked in fees from lively trading on stock and bond markets.

The bank is certain to face intense official scrutiny in months to come. The Swiss regulator, known as Finma, said it would “investigate in particular possible shortcomings in risk management” at Credit Suisse. Finma also said that it would “continue to exchange information with the competent authorities in the U.K. and the U.S.A.”

Mr. Gottstein acknowledged Thursday that the bank had received inquiries from regulators in the United States and Britain, but did not give details.

He declined to confirm a report in the The Wall Street Journal that Credit Suisse’s exposure to Archegos had reached more than $20 billion before the fund collapsed in late March. Mr. Gottstein conceded that Credit Suisse was one of the banks most exposed to Archegos.

The quarterly loss, which Mr. Gottstein described as “unacceptable,” compared with a profit of 1.3 billion francs in the first quarter of 2020.

Christine Lagarde, the president of the European Central Bank, which said it would continue buying government and corporate bonds to prevent “a tightening of financing conditions.”Credit…Daniel Roland/Agence France-Presse — Getty Images

The European Central Bank on Thursday maintained a stimulus program intended to counteract the economic effects of the pandemic, as expected, while promising to make sure that eurozone businesses and consumers have an ample supply of credit.

Following a monetary policy meeting, the bank’s Governing Council said in a statement that it would continue buying government and corporate bonds to prevent “a tightening of financing conditions that is inconsistent with countering the downward impact of the pandemic.”

At its last meeting, in March, the bank stepped up the pace of the bond purchases, a form of printing money that helps keep market interest rates low. The bank has also been funneling money directly to commercial banks at negative interest rates, provided they lend the money to customers.

The central bank said Thursday that it had seen “a high takeup” of the money, which is essentially free to lenders.

An AirTag, which Apple introduced this week as an attachment that helps owners find lost items, and which Tile says is a copy of its trackers.Credit…Apple, via Reuters

Tile said Apple boxed out its products and then copied them. Spotify said Apple blocked it from telling customers that they could find cheaper prices outside its iPhone app. And Match Group testified that it now paid nearly $500 million a year to Apple and Google in app store fees, the dating company’s single largest expense.

That testimony came Wednesday at a Senate hearing on Apple’s and Google’s control over their app stores, held by the Judiciary subcommittee on antitrust. The hearing was the latest example of the growing scrutiny of Big Tech and the increasing agreement among Democrats, Republicans and smaller companies that the world’s biggest tech companies have become too powerful.

At the hearing, representatives from Apple and Google defended their companies’ practices, saying that they don’t copy competitors, that few apps pay their commissions and that they charge the commissions to fund the security of their app stores.

Both Democratic and Republican senators were skeptical of those explanations. “Google and Apple are here to defend the patently indefensible,” said Senator Richard Blumenthal, a Democrat from Connecticut. “If you presented this fact pattern in a law school antitrust exam, the students would laugh the professor out of the classroom, because it is such an obvious violation of our antitrust laws.”

Apple and Google have long had a stranglehold on the business of mobile apps. But that position, which has earned them hundreds of billions of dollars, has increasingly led to regulatory, legal and public-relations headaches.

Federal and state lawmakers are holding hearings and considering legislation to weaken the companies’ app-store controls. The Justice Department is investigating the issue. And in a trial next month, Apple is set to face off against Epic Games, the Fortnite maker, which is suing Apple for forcing it to use Apple’s payment system in its iPhone app.

Jared Sine, the chief legal officer at Match Group, said on Wednesday that Google had called his company the previous night when his planned testimony became public. He said Google wondered why his testimony appeared to be tougher than what Match had said on a recent earnings call.

Mr. Blumenthal called that intimidation, and Senator Amy Klobuchar, the Minnesota Democrat who is the subcommittee’s chairwoman, suggested that the senators would investigate.

Wilson White, a government affairs official at Google, said that Match was an important partner and that Google would never aim to intimidate the company.

“There are many, many ways they could hurt our business,” Mr. Sine said. “We’re all afraid, is the reality, Senator. We’re fortunate you’re listening to us today.”

“Well,” Ms. Klobuchar replied, “I hope the Justice Department is, too.”

Gary Gensler will have ample chances to put his imprint on the Securities and Exchange Commission as its new chairman.Credit…Kayana Szymczak for The New York Times

The market may already be dictating some of the agenda for Gary Gensler, who started as chairman of the Securities and Exchange Commission on Saturday.

Mr. Gensler already has a lot on his plate, Matthew Goldstein reports for The New York Times:

  • One of the first things he will probably have to weigh in on is whether to assert more control over the red-hot market for special purpose acquisition companies, or SPACs, those speculative businesses that have raised well over $100 billion from investors.

  • He must also decide whether the S.E.C. should do more to protect small investors, who have recently become a major force in the stock markets.

  • Then there’s Archegos Capital Management, the $10 billion fund whose implosion last month spotlighted the loosely regulated world of family offices.

“Gensler is going to be confronted with a range of enforcement issues, and he is going to have to determine what his priorities are,” said Daniel Hawke, a former chief of the S.E.C.’s market abuse unit and now a partner with the law firm Arnold & Porter.

Dennis Kelleher, chief executive of Better Markets, a nonprofit organization, said he expected Mr. Gensler to focus on reforming the rules around corporate disclosures — including seeking more transparency from companies and big investors on their risks from climate change and contributions to it, as well as diversity on company boards — because it affected much of his agenda.

“Disclosure writ large will be a common thread through all the issues,” Mr. Kelleher said. “The S.E.C. is fundamentally a disclosure agency, and through better disclosure, you are supposed to be able to empower investors and enable enforcement.”

Arrival says its microfactories should produce vans that cost a lot less than other electric models and even today’s diesel vehicles.Credit…Andrew Testa for The New York Times

Arrival, a small electric vehicle company, is creating highly automated “microfactories” where its delivery vans and buses will be assembled by multitasking robots, breaking from the approach pioneered by Henry Ford and used by most of the world’s automakers.

The advantage, according to Arrival, is that its microfactories will cost about $50 million rather than the $1 billion or more required to build a traditional factory, Neal E. Boudette reports for The New York Times.

“The assembly line approach is very capital-intensive, and you have to get to very high production levels to make any margin,” said Avinash Rugoobur, Arrival’s president and a former General Motors executive. “The microfactory allows us to build vehicles profitably at really any volume.”

The company is also replacing most steel parts used in vehicles with components made from advanced composites, a mix of polypropylene, a polymer used to make plastics, and fiberglass. These parts are to be held together by structural adhesives instead of metal welds.

The use of composites, which can be produced in any color, would eliminate three of the most expensive parts of an auto plant — the paint shop, the giant printing presses that stamp out fenders and other parts, and the robots that weld metal parts into larger underbody components. Each typically costs several hundred million dollars.

The company, which is based in London and is setting up factories in England and the United States, says this method should yield vans that cost a lot less than other electric models and even today’s standard, diesel-powered vehicles.

A wind farm off Blackpool, England, operated by Orsted. Shares in renewable energy companies rose Thursday as nations made commitments to reduce greenhouse gas emissions.Credit…Phil Noble/Reuters

Shares in renewable energy companies rose as President Biden’s two-day climate summit began on Thursday, designated as Earth Day. Mr. Biden is expected to announce that the United States will intend to cut greenhouse gas emissions nearly in half by the end of the decade.

Ahead of the virtual summit with dozens of world leaders, Britain has also sped up its own climate change targets. On Tuesday, it set a new target of cutting emissions by nearly 80 percent by 2035, compared with 1990 levels. On Wednesday, the European Union agreed to a new target to reduce net emissions at least 55 percent by the end of the decade.

“As governments around the world look to kick-start their recoveries as well as reach climate goals, green spending has become one avenue for doing so,” strategists at UBS Global Wealth Management wrote in a note. “We think the sustainable investment universe will continue to expand rapidly.”

Shares in Orsted, a Danish wind energy company, rose 3.4 percent on Thursday, ending a eight-day streak of losses. Shares in Siemens Gamesa Renewable Energy jumped nearly 6 percent. First Solar shares rose in premarket trading, extending a gain of 5.4 percent from Wednesday. The iShares Global Clean Energy exchange-traded fund, which has $5.6 billion in assets, rose 2 percent on Wednesday and kept climbing in premarket trading.

  • U.S. stock futures were little changed. The Stoxx Europe 600 index rose 0.5 percent.

  • Credit Suisse shares plunged 6 percent on Thursday after the Swiss bank said it suffered a loss in the first quarter after billions of francs were lost because of loans made to investment fund Archegos Capital Management

  • The euro rose 0.2 percent against the dollar before the European Central Bank announces its latest monetary policy decisions. Economists are not expecting a change after the bank ramped up the pace of its bond buying program at its previous meeting in March.

Categories
Health

Elizabeth Holmes denies destroying proof in Theranos case

Elizabeth Holmes, founder and former executive director of Theranos, arrives for a hearing in the U.S. District Court in the Federal Building of Robert F. Peckham in San Jose, California on Monday, November 4, 2019.

Yichuan Cao | NurPhoto | Getty Images

The mystery of what happened to critical evidence proving Theranos’ blood testing technology was not working deepened when Elizabeth Holmes accused the government of what she calls an “investigative failure”.

In a file filed late Tuesday, Holmes lawyers shot back prosecutors to rule out evidence of so-called test results, saying they were to blame for losing a database called the Laboratory Information System (LIS) that contained three years of accuracy and failure rates of Theranos tests.

“Rather than accepting responsibility for this investigation failure and the resulting gaps in evidence in their case, the government has taken a different path,” write Holmes’ attorneys, adding, “The government has assumed that the loss of LIS data reflects the woman . Holmes’ alleged guilt, although it had nothing to do with it. “

“The reason the government lacks this evidence is because prosecutors sat on their hands for years before attempting to acquire them and then sat on their hands again after acquiring them. It is entirely their fault,” the lawyers write from Holmes.

“The reason the government built their case on this fluctuating house of cards of irrelevant evidence is because they lost – or, worse, didn’t want to analyze – the actual evidence of the test results in this case,” argued Holmes’ attorneys.

However, prosecutors claim that Theranos executives destroyed the LIS system, which proved their blood test product was inaccurate.

In a filing last month, the government said that three months after a federal grand jury issued a subpoena for a copy of the database in August 2018, “the LIS was destroyed”. They wrote that “the government was never given the full records in the LIS, nor were they given the tools available in the database to search for evidence as critical as any Theranos blood test with validation errors. The Data disappeared “”

Prosecutors say the failure rate in one of these tests was 51.3%, adding that Theranos’ test results “were so inaccurate that it was essentially a toss of a coin whether the patient got the correct result. The data was devastating.” You want to invite 11 patients and 11 physicians to testify about the accuracy and reliability issues.

Holmes says there is a certain amount of expected errors in all laboratory tests: “Just as the fact of a heart attack does not prove what caused the heart attack, the fact of a wrong blood test does not prove what caused the error.”

Prosecutors point to internal emails that prove Theranos and his lawyer tried to cover up the grand jury’s test results in the database. Theranos provided backup copies of the database for investigators to put together. However, prosecutors claim that the backup required a password that Theranos executives could not remember.

Once a Silicon Valley darling, Theranos attracted the who’s who of venture capitalists and a $ 9 billion private valuation before closing in 2018.

Holmes and her co-defendant Ramesh “Sunny” Balwani each face a dozen fraud charges related to deceiving investors, patients and doctors about Theranos technology.

Holmes will face prosecutors next month for believing that evidence should not be presented to a jury that will determine her fate.

The judge’s verdicts will set the stage for her long-awaited trial, due to begin in July.

Categories
Health

Proof Builds That Pregnant Girls Cross Covid Antibodies to Newborns

One of the many big questions scientists are trying to unravel is whether people who receive Covid-19 while pregnant pass natural immunity to their newborns.

Recent studies have indicated that this could be the case. New findings published in JAMA Pediatrics magazine on Friday are another piece of the puzzle that provides more evidence that Covid-19 antibodies can cross the placenta.

“What we found agrees pretty well with what we learned from studies with other viruses,” said Scott E. Hensley, associate professor of microbiology at the Perelman School of Medicine at the University of Pennsylvania and a leading author of the study.

In addition, the study suggests that women not only transfer antibodies to their fetuses, but also transfer more antibodies to their babies if they are infected earlier in pregnancy. This could have an impact on when women should be vaccinated against Covid-19, said Dr. Hensley, adding that vaccinating women earlier in pregnancy could provide more protective benefits, “but studies that actually analyze vaccination in pregnant women need to be completed.”

In the study, researchers from Pennsylvania tested more than 1,500 women who gave birth at the Pennsylvania Hospital in Philadelphia between April and August last year. Of these, 83 women had Covid-19 antibodies – and after birth, 72 of these babies tested positive for Covid-19 antibodies through their umbilical cord blood, regardless of whether their mothers had symptoms.

According to Dr. Karen Puopolo, an associate professor of pediatrics at the University of Pennsylvania and one of the study’s lead authors, found that about half of these babies had antibody levels that were as high or higher than those found in their mother’s blood, and about a quarter of the cases were Antibody levels in umbilical cord blood 1.5 to 2 times higher than the concentrations in the mother.

“That’s pretty efficient,” said Dr. Puopolo.

The researchers also observed that the longer the time span between a pregnant woman’s onset of Covid-19 infection and her delivery, the more antibodies were transferred, a finding noted elsewhere.

Updated

Jan. 30, 2021, 1:12 p.m. ET

The antibodies that crossed the placenta were immunoglobulin G or IgG antibodies made a few days after infection and believed to provide long-term protection against the coronavirus.

None of the babies in this study were found to have immunoglobulin M or IgM antibodies, which are typically not detected until soon after infection, suggesting that the babies were not infected with the coronavirus.

Experts don’t yet know if the amount of antibodies passed on to the babies was enough to prevent newborns from getting Covid-19. And because only some of the babies in the study were born prematurely, the researchers can’t say whether premature babies might miss these protective antibodies. The study’s authors also noted that the findings needed further replication as their findings only came from one facility.

The placenta is a complex and under-studied organ, said Dr. Denise Jamieson, an obstetrician at Emory University in Atlanta and a member of the Covid Expert Group at the American College of Obstetricians and Gynecologists who was not involved in the organ study.

More research is needed to better understand whether antibodies generated by vaccines behave similarly to antibodies against Covid-19 infections, said Dr. Andrea G. Edlow, Assistant Professor of Obstetrics, Gynecology, and Reproductive Biology at Harvard Medical School.

In a study published in Cell in December, Dr. For example, Edlow and her colleagues found that Covid-19 antibodies, due to a natural infection, may cross the placenta less efficiently than antibodies produced after vaccination against flu and whooping cough (pertussis). .

“What we really want to know is that antibodies from the vaccine efficiently cross the placenta and protect the baby as we know it to do with influenza and pertussis,” said Dr. Jamieson.

Experts don’t know if the Covid vaccine works this way, partly because pregnant women were excluded from the initial clinical trials.

“It is plausible that the Covid vaccine will offer protection to both pregnant mothers and their infants,” said Dr. Mark Turrentine, member of the Covid expert group at ACOG. “For me,” he added, “this study highlights the inclusion of pregnant women. Women in clinical trials such as the Covid-19 vaccine are critical, especially when the benefits of vaccination outweigh the potential risk of life-threatening illness. “

Categories
Health

Proof new UK Covid pressure could also be extra lethal

UK Prime Minister Boris Johnson speaks during a press conference on Coronavirus (COVID-19) on Downing Street on January 15, 2021 in London, England.

Dominic Lipinski | Getty Images

LONDON – There is “some evidence” that a new variant of Covid, first identified in the UK, could be more deadly than the original variety, UK Prime Minister Boris Johnson said Friday.

“We were informed today that not only is there a faster spread, but there is also evidence that the new variant – the variant first discovered in London and the south east (of England) – may be associated with a higher one Mortality rate, “Johnson told a press conference.

He added that all the evidence suggests that the vaccines from Pfizer-BioNTech and AstraZeneca-Oxford University, both of which are currently in use in the UK, will remain effective against both the old and new variants of the virus.

The evidence is still in a preliminary stage and is being assessed by the Advisory Group on New and Emerging Respiratory Virus Threats, which is advising the UK Government.

The variant known as B.1.1.7 has an unusually high number of mutations and was already associated with more efficient and faster transmission.

Scientists first discovered this mutation in September. It has since been found in at least 44 countries, including the US, which has reported its presence in 12 states.

Last week, the US Centers for Disease Control and Prevention warned that the US variant’s modeled trajectory “is growing rapidly in early 2021 and will become the predominant variant in March”.

Patrick Vallance, the UK’s chief scientific adviser, said alongside Johnson on Friday that there were early signs that the risk for those with the new variant was increased compared to the old virus.

“If you were to … take a man in his sixties, the average risk is that for every 1,000 people infected, about 10 would die from the virus. With the new variant, for 1,000 people infected, about 13 or 14 would be expected People are dying, “said Vallance.

He described the data as not yet strong and emphasized more concern about other variants of Covid in Brazil and South Africa.

– CNBC’s Sam Meredith contributed to this article.

Categories
Health

England’s third lockdown sees ‘no proof of decline’ in instances

Medics transfer a patient from an ambulance to the Royal London Hospital in London on January 19, 2021.

TOLGA AKMEN | AFP | Getty Images

LONDON – A third national lockdown in England appears to have had little impact on the rising rate of coronavirus infection, according to the results of a large study, with the prevalence of the virus showing “no signs of decline” in the first 10 days of the year, on a more severe basis Restrictions.

The closely watched REACT-1 study, led by Imperial College London, warned that if the prevalence of the virus in the community were not significantly reduced, the health system would remain under “extreme pressure” and the cumulative death toll would rise rapidly.

The results of the preprint report, released Thursday by Imperial College London and Ipsos MORI, come shortly after the UK recorded another all-time high in coronavirus deaths.

Government figures released on Wednesday showed an additional 1,820 people had died within 28 days of a positive Covid test. To date, the UK has registered 3.5 million coronavirus cases with 93,290 deaths.

UK Prime Minister Boris Johnson speaks during a press conference on Coronavirus (COVID-19) on Downing Street on January 15, 2021 in London, England.

Dominic Lipinski | Getty Images

Prime Minister Boris Johnson said the latest numbers were “appalling” and warned: “There are still difficult weeks ahead.”

Johnson imposed lockdown measures in England on January 5, ordering people to “stay home” as most schools, bars and restaurants had to close. The strict public health measures are expected to remain in place until at least mid-February.

What were the main results?

The REACT-1 study tests nasal and throat swabs roughly monthly from 120,000 to 180,000 people in the UK community. The most recent results mainly cover a period January 6-15.

The study compared the results of swabs collected between November 13 and 24 and those collected between November 25 and December 3.

The researchers found 1,962 positives from 142,909 swabs removed in January. This means that 1.58% of the people tested had Covid on a weighted average.

This corresponds to an increase in prevalence rates of more than 50% since the results of the study in mid-December and is the highest value REACT-1 has recorded since it began in May 2020.

The prevalence from January 6-15 was highest in London. According to one study, 1 in 36 people infected was more than twice as likely as the previous REACT-1 results.

A man wearing a mask as a preventive measure against the spread of Covid-19 goes for a walk in London.

May James | SOPA pictures | LightRocket via Getty Images

In the south-east of England, the east of England and the West Midlands, the infections had more than doubled compared to the results published in early December.

“Our data shows worrying evidence of a recent surge in infections that we will continue to monitor closely,” said Professor Paul Elliott, program director at Imperial, in a statement.

“We are all helping to keep this situation from getting worse and we must do our best to stay home wherever possible,” he added.

The UK Department of Health and Welfare said the full effects of the lockdown measures were not yet reflected in the prevalence figures reported in the REACT-1 study.

“These results show why we cannot be on our guard in the coming weeks,” said Health Secretary Matt Hancock.

“It’s absolutely essential that everyone does their part to help alleviate infection. This means staying at home and only going out where absolutely necessary, reducing contact with others and maintaining social distance,” said Hancock.